MedAnnex Ltd Receives SMART: Scotland R&D Award
Scottish Enterprise will contribute up to £423,000 towards the industrial development of a novel antibody to treat autoimmune diseases
Edinburgh, UK, 12 June 2018: MedAnnex Ltd, an innovative biotechnology company developing new therapies to treat autoimmune diseases, announced today that it has been awarded up to £423,000 via the SMART: SCOTLAND programme. Alongside backing from MedAnnex’s investors, this Scottish Enterprise award will co-fund critical industrial development work for the company’s novel antibody, annexuzlimab, which has the potential to become a ground-breaking autoimmune disease therapy.
In most cases, autoimmune diseases are life-changing, with high medical, social and financial burdens. Patients often develop resistance to existing therapies, many of which have serious side-effects, so there is an urgent need for new treatments.
To read the full article, click here.
Find out more about business support in Scotland here.